Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing new data from Phase II trial on Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced metastatic gastro-oesophageal adenocarcinoma (mGEA)

Ticker(s): JAZZ

Who's the expert?

Institution: St. Lukes

Attending Physician specializing in hematology and oncology
experience with and knowledgable about the use of bispecific antibiodies and bispecifics in development
treats 200 patients with Diffuse Large B-Cell Lymphoma

Interview Goal

This conversation will focus on Jazz Pharmacueticals' recent Phase II data on treatment through Zanidatamab with chemotherapy for advanced metastatic gastro-oesophageal adenocarcinoma.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.